I-Corps: Label-free Optical Sensor for Diagnostics

I-Corps项目在医疗保健领域的广泛影响/商业潜力是巨大的。这项拟议的技术可以在早期阶段检测到严重的医疗状况(如癌症)，从而潜在地提高生活质量和预期寿命。这项技术还可以扩展到通过优化纳米光子传感器来检测给定的一组生物标记物，在护理点诊断各种医疗情况(如心血管疾病)。除了医疗点诊断，以低成本检测多个血液生物标记物的可能性使预测性健康和个性化医疗等变革性领域成为可能。广泛的潜在变革性应用和广泛的目标客户为拟议的技术提供了令人信服的商业潜力。这个i-Corps项目专注于开发一种变革性的医疗诊断技术，用于对血液生物标志物的护理点检测，这些生物标志物在检测癌症等医疗疾病方面发挥着关键作用。靶诊断系统是一种低成本的光学生物芯片，通过消除或减少现有检测技术中昂贵且耗时的放大步骤，可以大幅降低检测成本。利用纳米光子技术检测不同的医学相关生物标志物，使超小型、高灵敏度和高度多元化的传感器的开发成为可能，这些传感器是包括癌症在内的多种医疗诊断场景中迫切需要的。在合理的时间内以高灵敏度和高特异度以低成本检测多个血液生物标志物的能力，将通过在护理点引入诊断工具，对医疗保健产生潜在的变革性影响。在各种纳米光子学解决方案中，使用高度微型化的等离子体纳米结构具有灵敏度高、成本低的优点。通过将这些纳米结构适当地设计成阵列，可以获得更高的灵敏度。

The broader impact/commercial potential of this I-Corps project in the area of healthcare is significant. The proposed technology can potentially improve the quality of life and life expectancy by allowing the detection of severe medical conditions (such as cancer) at the early stages. The technology can also be extended to diagnose a large variety of medical situations (such as cardiovascular diseases) at the point of care through optimization of the nanophotonic sensor for the detection of a given set of biomarkers. Beyond point-of-care diagnostics, the possibility of detecting multiple blood biomarkers at a low cost enables transformative fields such as predictive health and personalized medicine. The wide range of potential transformative applications and the extensive range of target customers give a compelling commercial potential to the proposed technology.This I-Corps project is focused on the development of a transformative medical diagnostic technology for the point-of-care detection of blood biomarkers that play a crucial role in detection of medical conditions such as cancer. The target diagnostic system is a low-cost optical bio-chip that can drastically decrease the assaying cost by eliminating or reducing the need for costly and time-consuming amplifications steps in the existing detection technologies. The use of nanophotonic technology for detection of different medically relevant biomarkers enables the development of ultra-compact highly sensitive, and highly multiplexed sensors that are urgently needed for multiple medical diagnostic scenarios, including cancer. The ability to detect multiple blood biomarkers in a reasonable time with high sensitivity and specificity at a low cost will have a potentially transformative impact on healthcare by bringing diagnostic tools at the point-of-care. Among various nanophotonic solutions, the use of highly miniaturized plasmonic nanostructures has the advantage of higher sensitivity and lower cost. By proper engineering of these nanostructures into an array, higher sensitivity can be achieved.